Terms: = Colorectal cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Clinical Outcome
19 results:
1. N6-methyladenosine reader protein IGF2BP1 suppresses CD8 + T cells-mediated tumor cytotoxicity and apoptosis in colon cancer.
Peng Y; Zhang Z; Yang G; Dai Z; Cai X; Liu Z; Yun Q; Xu L
Apoptosis; 2024 Apr; 29(3-4):331-343. PubMed ID: 37848671
[TBL] [Abstract] [Full Text] [Related]
2. Immune Marker Spatial Distribution and clinical outcome after PD-1 Blockade in Mismatch Repair-deficient, Advanced colorectal Carcinomas.
Saberzadeh-Ardestani B; Graham RP; McMahon S; Ahanonu E; Shi Q; Williams C; Hubbard A; Zhang W; Muranyi A; Yan D; Jin Z; Shanmugam K; Sinicrope FA
Clin Cancer Res; 2023 Oct; 29(20):4268-4277. PubMed ID: 37566222
[TBL] [Abstract] [Full Text] [Related]
3. Spatially resolved multimarker evaluation of cd274 (pd-l1)/PDCD1 (PD-1) immune checkpoint expression and macrophage polarisation in colorectal cancer.
Elomaa H; Ahtiainen M; Väyrynen SA; Ogino S; Nowak JA; Lau MC; Helminen O; Wirta EV; Seppälä TT; Böhm J; Mecklin JP; Kuopio T; Väyrynen JP
Br J Cancer; 2023 Jun; 128(11):2104-2115. PubMed ID: 37002343
[TBL] [Abstract] [Full Text] [Related]
4. A novel prognostic immunoscore based on The cancer Genome Atlas to predict overall survival in colorectal cancer patients.
Tang Z; Wu Y; Sun D; Xue X; Qin L
Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34608935
[TBL] [Abstract] [Full Text] [Related]
5. Systemic Inflammation Associates With a Myeloid Inflamed Tumor Microenvironment in Primary Resected Colon cancer-May Cold Tumors Simply Be Too Hot?
Køstner AH; Nielsen PS; Georgsen JB; Parner ET; Nielsen MB; Kersten C; Steiniche T
Front Immunol; 2021; 12():716342. PubMed ID: 34531864
[TBL] [Abstract] [Full Text] [Related]
6. Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with microsatellite-stable colorectal liver metastases.
Stift J; Graf A; Neudert B; Herac M; Woeran K; Tamandl D; Laengle J; Schwarz C; Wrba F; Kaczirek K; Stremitzer S
HPB (Oxford); 2022 Jan; 24(1):40-46. PubMed ID: 34158230
[TBL] [Abstract] [Full Text] [Related]
7. Impact of pd-l1 and PD-1 Expression on the Prognostic Significance of CD8
Munari E; Marconi M; Querzoli G; Lunardi G; Bertoglio P; Ciompi F; Tosadori A; Eccher A; Tumino N; Quatrini L; Vacca P; Rossi G; Cavazza A; Martignoni G; Brunelli M; Netto GJ; Moretta L; Zamboni G; Bogina G
Front Immunol; 2021; 12():680973. PubMed ID: 34122444
[TBL] [Abstract] [Full Text] [Related]
8. Removal of N-Linked Glycosylation Enhances pd-l1 Detection in Colon cancer: Validation Research Based on Immunohistochemistry Analysis.
Xu J; Yang X; Mao Y; Mei J; Wang H; Ding J; Hua D
Technol Cancer Res Treat; 2021; 20():15330338211019442. PubMed ID: 34060360
[TBL] [Abstract] [Full Text] [Related]
9. CD30
Lam JH; Hong M; Koo SL; Chua CWL; Lim KL; Wee F; Wan WK; Leow WQ; Yeo JG; Tan IBH; Yeong J; Lim TKH; Lim TS
Cancer Immunol Immunother; 2021 Aug; 70(8):2353-2365. PubMed ID: 33527196
[TBL] [Abstract] [Full Text] [Related]
10. The Latest Findings of PD-1/pd-l1 Inhibitor Application in Gynecologic cancers.
Kooshkaki O; Derakhshani A; Safarpour H; Najafi S; Vahedi P; Brunetti O; Torabi M; Lotfinejad P; Paradiso AV; Racanelli V; Silvestris N; Baradaran B
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708748
[TBL] [Abstract] [Full Text] [Related]
11. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
Kitsou M; Ayiomamitis GD; Zaravinos A
Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
[TBL] [Abstract] [Full Text] [Related]
12. Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation.
Ortega Sanchez G; Stenner F; Dirnhofer S; Passweg J; Gerull S; Halter JP; Zippelius A; Läubli H
Swiss Med Wkly; 2019 Nov; 149():w20150. PubMed ID: 31707719
[TBL] [Abstract] [Full Text] [Related]
13. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome.
Fakih M; Ouyang C; Wang C; Tu TY; Gozo MC; Cho M; Sy M; Longmate JA; Lee PP
J Clin Invest; 2019 Oct; 129(10):4464-4476. PubMed ID: 31524634
[TBL] [Abstract] [Full Text] [Related]
14. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/pd-l1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract] [Full Text] [Related]
15. Results and challenges of immune checkpoint inhibitors in colorectal cancer.
Emambux S; Tachon G; Junca A; Tougeron D
Expert Opin Biol Ther; 2018 May; 18(5):561-573. PubMed ID: 29471676
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer.
Wang L; Liu Z; Fisher KW; Ren F; Lv J; Davidson DD; Baldridge LA; Du X; Cheng L
Hum Pathol; 2018 Jan; 71():20-29. PubMed ID: 28782638
[TBL] [Abstract] [Full Text] [Related]
17. Application of the Immunoscore as prognostic tool for hepatocellular carcinoma.
Petrizzo A; Buonaguro L
J Immunother Cancer; 2016; 4():71. PubMed ID: 27879973
[TBL] [Abstract] [Full Text] [Related]
18. The tumor suppressor miR-138-5p targets pd-l1 in colorectal cancer.
Zhao L; Yu H; Yi S; Peng X; Su P; Xiao Z; Liu R; Tang A; Li X; Liu F; Shen S
Oncotarget; 2016 Jul; 7(29):45370-45384. PubMed ID: 27248318
[TBL] [Abstract] [Full Text] [Related]
19. Significance of Programmed Death Ligand 1 (pd-l1) Immunohistochemical Expression in colorectal cancer.
Wang L; Ren F; Wang Q; Baldridge LA; Monn MF; Fisher KW; Sheng W; Zhou X; Du X; Cheng L
Mol Diagn Ther; 2016 Apr; 20(2):175-81. PubMed ID: 26891728
[TBL] [Abstract] [Full Text] [Related]
